Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01178827 · ClinicalTrials.gov registry record · Phase 4
Sanctura Muscarinic Receptor Antagonist Resists Transport (SMART-II) Trial
A Phase 4 study, sponsored by Allergan.
- Completed
- Registry status
- Phase 4
- Development phase
- 20
- Enrollment target
NCT01178827 is a Phase 4 study that has completed, run by Allergan. The registered enrollment target is 20 participants.
The verdict
NCT01178827, a Phase 4 study, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 20 participants
- Enrollment target
Study Summary
This study will evaluate the cerebrospinal fluid levels of trospium chloride (Sanctura XR®) and oxybutynin immediate release (Oxybutynin IR) on memory performance in patients with overactive bladder and age associated memory impairment.
Interventions
- DRUG trospium chloride
- DRUG oxybutynin IR
- DRUG oxybutynin IR placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2010-08 |
| Est. Completion | 2011-03 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01178827
The ClinicalTrials.gov registry entry for NCT01178827 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allergan, which has 314 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which trospium chloride is the first listed.
NCT01178827 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01178827 about?
NCT01178827 is a clinical study titled "Sanctura Muscarinic Receptor Antagonist Resists Transport (SMART-II) Trial". This study will evaluate the cerebrospinal fluid levels of trospium chloride (Sanctura XR®) and oxybutynin immediate release (Oxybutynin IR) on memory performance in patients with overactive bladder and age associated memory impairment.
What is the current status of trial NCT01178827?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 20 participants. The study started on 2010-08. Estimated completion is 2011-03.
What interventions are being tested in trial NCT01178827?
The interventions under investigation include: trospium chloride (DRUG), oxybutynin IR (DRUG), oxybutynin IR placebo (DRUG).
Who is sponsoring clinical trial NCT01178827?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.